December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.77 +0.37 (+0.79%)
Streaming Delayed Price Updated: 2:12 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? ↗
Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours. 
Via MarketBeat
Topics Intellectual Property Lawsuit
News headline image
Why Hims & Hers Health Stock Just Crashed ↗
Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year. 
Via The Motley Fool
Topics Earnings Lawsuit
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
News headline image
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? ↗
The weight loss drug market is on track to reach almost $100 billion. 
Via The Motley Fool
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus ↗
As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth. 
Via MarketBeat
News headline image
Forget Eli Lilly: These 2 Stocks Have More Upside ↗
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors. 
Via The Motley Fool
News headline image
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims ↗
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits. 
Via MarketBeat
News headline image
My Top Obesity Stock to Buy and Hold ↗
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand. 
Via The Motley Fool
Record Highs, Punished Results, and One Very Consequential Apple Rumor ↗
Via Chartmill
News headline image
3 Absurdly Cheap Growth Stocks to Buy in May 2026 ↗
These stocks have been struggling over the past year, but their growth days are far from over. 
Via The Motley Fool
News headline image
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗
The Street is bullish on this biotech's prospects, but is the sentiment justified? 
Via The Motley Fool
News headline image
Eli Lilly Just Announced Fantastic News for Shareholders ↗
Lilly's weight loss drugs have been delivering blockbuster revenue. 
Via The Motley Fool
Topics Earnings
News headline image
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) ↗
The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline. 
Via The Motley Fool
News headline image
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent ↗
Via MarketBeat
News headline image
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗
Via MarketBeat
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
News headline image
Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So ↗
And he may be right. 
Via The Motley Fool
News headline image
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means ↗
Via MarketBeat
News headline image
Is This Deal a Game Changer for Novo Nordisk? ↗
The drugmaker is getting on the AI train in ways that could move the needle down the road. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly ↗
Eli Lilly has more to offer than some investors realize. 
Via The Motley Fool
News headline image
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗
Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full. 
Via The Motley Fool
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
The weight loss drug market may reach almost $100 billion in a few years. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Flopped on Friday ↗
High hopes for a freshly approved drug might not be realized, if early data is any indication. 
Via The Motley Fool
News headline image
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) ↗
A rival company's trial results had a negative impact on Agios' stock this week. 
Via The Motley Fool
News headline image
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗
Novo Nordisk stock has been stuck in a downward spiral for quite some time. 
Via The Motley Fool
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.